Compare CODX & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODX | NVNO |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 16.7M |
| IPO Year | 2017 | N/A |
| Metric | CODX | NVNO |
|---|---|---|
| Price | $0.18 | $0.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.25 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 439.1K |
| Earning Date | 11-13-2025 | 10-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $507,892.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $0.30 |
| 52 Week High | $1.55 | $5.62 |
| Indicator | CODX | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 30.03 | 40.63 |
| Support Level | $0.22 | $0.32 |
| Resistance Level | $0.30 | $0.37 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 2.05 | 51.80 |
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.